MedTrace Logo

Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients

NCT01049711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2015-09-29

No results posted yet for this study

Summary

To study the cost utility analysis of Erythropoietin (EPO) for maintaining the different hemoglobin (Hb) target levels in anemic hemodialysis patient in routine clinical practice.

Conditions

  • Chronic Renal Failure

Interventions

DRUG

erythropoietin

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Tanita Thaweethamcharoen, Ph.D · Faculty of Medicine, Mahidol University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-02-28
Completion
2010-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049711 on ClinicalTrials.gov